Eli Lilly disclosed blockbuster demand for tirzepatide, reporting about $10.1 billion in third‑quarter sales and raising its full‑year outlook as the medicine becomes the world’s top‑selling drug. The performance highlights the commercial dominance of GLP‑1–based and related metabolic therapies and intensifies competitive dynamics with Novo Nordisk and others. Lilly’s earnings beat and guidance raise lifted investor enthusiasm but also stoked debate about market sustainability, access, and pricing as payers and regulators eye broader policy responses to rapid uptake of weight‑loss drugs.